Partnership underscores Agilent’s expansion across Asia, including recent establishment of Centres of Excellence (CoEs) within flagship university campuses in South Korea, Singapore and Malaysia

MELBOURNE, Australia, Nov. 12, 2025 /PRNewswire/ — Agilent Technologies Inc. (NYSE: A) announced the launch of its new Agilent Innovation Hub in partnership with the University of Melbourne, acting through the Australian Laboratory for Emerging Contaminants (ALEC). The hub integrates Agilent’s next-generation technologies, including an extensive portfolio of Infinity III Liquid Chromatography (LC) systems and ALEC’s research expertise in the critical area of environmental health and safety.     

“This collaboration with Agilent shows what’s possible when academia and industry work hand in hand. It allows us to move beyond measuring known contaminants toward discovering the thousands of unregulated chemicals that may be circulating in our environment and bodies. That knowledge is essential for protecting communities and informing smart regulation.” Said Assoc. Prof. Brad Clarke at University of Melbourne.

This marks the second collaboration between Agilent and the University of Melbourne in the context of emerging contaminant research addressing Australia’s priorities in improving population health. Under the technical refresh program, led by renowned Australian environmental scientist Assoc. Prof. Brad Clarke, research will tackle new pollutants, from synthetic per-and polyfluoroalkyl substances (PFAS) to microplastics and flame retardants, driving cutting-edge solutions developed in Australia for Australia.

“We are proud to launch the Agilent Innovation Hub with ALEC, advancing biomonitoring insights while driving environmental research to improve population health in Australia. Leveraging our 6495C Triple Quad LC and LDIR systems, we’ve pioneered ultra-trace detection, achieving world-class breakthroughs in parts per quadrillion (PPQ)-level quantitation of PFAS and microplastics in drinking water^[1]. This partnership further solidifies Agilent’s leadership in innovation and reinforces our strategic expansion across Asia, following the establishment of Centres of Excellence (CoEs) within flagship university campuses in South Korea, Singapore, and Malaysia.” Said Bharat Bhardwaj, vice president of APAC sales at Agilent.

At the heart of the Agilent Innovation Hub is a commitment to strengthening the discovery pipeline by combining new capabilities across InfinityLab Assist Technology, InfinityLab Level Sensing, InfinityLab Sample ID Reader, and high-resolution Revident Quadruple Time of Flight LC/MS. Together, these innovations elevate automation and accuracy, allowing scientists to identify previously undetected compounds with unmatched precision. 

Since 2017, Agilent’s long-term collaboration with Assoc. Prof. Brad Clarke has driven continuous innovation, from early studies using Agilent’s 6495B Triple Quad LC/MS system to a pivotal 2019 application note publication. This momentum led to the 2020 establishment of the ALEC research facility, with Agilent as one of its founding industry partners, further advancing Australia’s leadership in environmental analysis and sustainable scientific innovation.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Media Contact

CG-0416, a highly liver-targeted THR-β agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination with GLP-1 RAs.

ATLANTA, Nov. 12, 2025 /PRNewswire/ — CureGene Pharmaceuticals (“CureGene”) today announced the first disclosure of groundbreaking preclinical data for CG-0416, a novel oral non-GLP-1 weight-loss agent, in the Late-Breaking poster session (Poster-350) at Obesity Week 2025. CG-0416 is a highly liver-targeting thyroid hormone receptor beta (THR-β) agonist. Its highlighted profile—oral administration, potent fat reduction, and muscle preservation, and without GLP-1 target associated side effects—positions it as a potential new paradigm that could advance global obesity treatment beyond current GLP-1-based therapies.

While GLP-1 receptor agonists like semaglutide have demonstrated significant efficacy, they are associated with core challenges including muscle loss, gastrointestinal (GI) side effects, and the inconvenience of injectable administration. CG-0416 has been designed to address these limitations through a distinct mechanism. It precisely activates the THR-β receptor in the liver, directly boosting hepatic metabolism to promote fat burning and energy expenditure, without acting on the central appetite control system. This peripheral mechanism fundamentally avoids the potential psychiatric affects and GI adverse events associated with potent appetite suppression and effectively protects muscle tissue.

High-Quality Weight Loss: CG-0416 Monotherapy Achieves “Fat Loss, Not Muscle Loss”

Data presented revealed that in diet-induced obese (DIO) mouse models, CG-0416 monotherapy demonstrated superior “high-quality weight loss.” While achieving weight reduction comparable to semaglutide (Figure 1), approximately 95% of the weight loss with CG-0416 came from fat mass reduction, with minimal muscle loss. In contrast, about one-third of semaglutide-induced weight loss was attributed to lean mass reduction. By not strongly suppressing appetite, CG-0416 is expected to significantly reduce nausea, vomiting, and other GI adverse events, potentially leading to better patient adherence (Figure 2). Furthermore, CG-0416 significantly reduced blood and liver lipid levels and improved glucose tolerance, offering comprehensive metabolic benefits.

Synergistic Effects: CG-0416 in Combination with GLP-1 RAs Breaks Limits in Weight Loss and Remodel the Metabolizing Profile

The studies further explored combination therapies of CG-0416 with various GLP-1 RAs, including semaglutide and oral orforglipron, revealing powerful “1+1>2” synergistic effects.

• Combination with semaglutide: The combination increased weight loss from 24% (semaglutide monotherapy) to 40%, with some obese mice returning to a healthy weight range. It also significantly mitigated the muscle loss associated with GLP-1 RA monotherapy, increasing body muscle percentage. (Figure 3)
• Combination with orforglipron: Similar synergistic effects were observed, confirming the robustness of this approach. (Figure 4)

This innovative dual-pathway strategy—combining “central appetite regulation (GLP-1 RA) + peripheral liver metabolism activation (CG-0416)”—offers a novel solution for patients requiring profound weight loss and metabolic restoration.

Broad Application Potential Meets Diverse Needs

As a once-daily oral agent, CG-0416 greatly enhances convenience and patient compliance. Its unique advantages cover the needs from different patient populations:

• CG-0416 Monotherapy: Ideal for individuals seeking healthy status (fat loss and muscle preservation) and for patients intolerant to GLP-1-based therapies.
• CG-0416 + GLP-1 RA Combination: Provides a more potent, higher-quality (with reduced muscle loss), and sustainable treatment option for patients with obesity and metabolic syndrome.

The data presented firmly establish the strong potential of CG-0416 as a “next-generation benchmark weight-loss therapy” and further validate the efficiency of CureGene’s “Jade” prodrug technology platform. CG-0416 represents not merely a supplement to existing treatments, but a critical step toward a future of high-quality, sustainable, and personalized weight management.

About Obesity Week 2025

Obesity Week 2025 is the world’s premier international event focused on obesity research and treatment. Co-convened by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS), the conference takes place in November in the United States. It brings together experts from multiple disciplines including surgery, endocrinology, nutrition, and behavioral science to present the latest advancements in obesity research, prevention, and treatment, including pharmacology, surgery, and lifestyle intervention. As a key industry bellwether, Obesity Week 2025 is a critical platform for announcing major research findings and fostering cross-disciplinary collaboration, dedicated to advancing the science of obesity and improving patient care worldwide.

About CureGene

Founded in 2018 and headquartered in China, CureGene is a clinical-stage biotech company advancing novel therapies for global unmet medical needs. Leveraging proprietary technology platforms, the company has built a diversified pipeline of first-in-class candidates with full global intellectual property rights. Current focus areas include cardio-cerebrovascular disorders, antiviral therapies, and metabolic dysregulation. Its interdisciplinary team integrates world-class scientists and industry veterans from leading multinational pharmaceutical companies, driving rapid translation from discovery, clinical development and commercialization. All pipeline assets are strategically positioned to address multibillion-dollar therapeutic markets, with lead programs demonstrating potential for best-in-class efficacy across preclinical and clinical studies.

Forward-Looking Statement

The information released in this press release may contain certain forward-looking statements (such as “will”, “anticipate”, “forecast”, “expect”, “intend”, “plan”, “believe”, “estimate”, “be confident” and other similar expressions), which are based on the current views, beliefs and expectations that the Company or its management has towards the Company’s business operations and financial performance when such statements are made. These forward-looking statements shall not be deemed as guarantees of future outcomes, and such outcomes may be affected by risks, uncertainties, and other factors, some of which are beyond the Company’s control and difficult to predict. Therefore, subject to the impacts of our business, general industry conditions and competition, environment, politics, general economic factors (including fluctuations in interest rates and exchange rates), pharmaceutical industry regulations and medical policies, technological developments, new products and patents obtained by any competitors, the inherent challenges in new product development (including obtaining regulatory approvals), production difficulties or delays, instability in the international economic and financial situation and sovereign risks, reliance on the effectiveness of the protection of the Company’s patents and other innovative products, the Company’s risks of facing patent litigation and/or regulatory actions, future changes and developments in social situations and other various factors and assumptions, the actual results may differ significantly from the information contained in the forward-looking statements.
Such forward-looking statements shall not in any way be considered as any commitments/guarantee made by the Company, its subsidiaries, or any of its directors, officers, management personnel, advisors, employees and/or agents regarding relevant matters. They do not constitute a recommendation to engage in a certain act. None of such personnel assumes any liability with respect to such forward-looking statements. Moreover, the Company and its subsidiaries, directors, management personnel, consultants, employees and/or agents have not and will not assume any responsibility for updating the forward-looking statements contained in this press release to reflect the latest information, future projects or circumstances or events that occur after the release date.

MELBOURNE, Australia, Nov. 12, 2025 /PRNewswire/ — Insta360, the global leader and best-selling 360° camera innovators, have announced the opening of their first Australian retail store bringing their immersive world to Melbourne’s Chadstone Shopping Centre from November 18th 2025.

This major milestone marks a further step for Insta360’s journey into the Australian market, bringing its award-winning technology and global creator community together under one roof. Designed to be an experience-led space, Insta360 invites visitors to step in and try, learn and play with their latest products – including the X5 and Go Ultra – the brand’s most advanced cameras to date.

“Opening our first store in Australia is an exciting milestone for Insta360,” said Max Richter, VP of Marketing and Co-Founder at Insta360. “Melbourne was a natural fit for us given the thriving community, creativity and culture. We can’t wait to welcome everyone from novice photographers through to adventure enthusiasts giving them a place to connect, learn, and be inspired by what’s possible in photography.”

Insta360 X5 – Taking everyday moments and making them cinematic

Loved by Marc Marquez, seven-time MotoGP Champion, the X5 is the ultimate compact camera to push to the limit. The X5 sets a new benchmark for imaging with 360º degree capture, large 1/1.28″ sensors to capture true to life colours with brighter, richer visuals at 8K30fps. What’s more, X5 is packed with features including Invisible Selfie Stick Effect, durable and replaceable lenses and over 208 minutes of battery life for unlimited storytelling possibilities.

Insta360 Go Ultra – The world’s most portable action camera

Tiny and hands-free, the Go Ultra redefines on-the-go shooting with unmatched versatility and stabilisation. Think hands-free POV to effortlessly capture from your perspective, tiny at only 53g but mighty Ultra HD 4K60fps and huge 1/1.28″ sensor and 5nm AI chip – this is the palm-sized powerhouse that will give you complete artistic freedom.

To celebrate this launch, Insta360 will be hosting a Grand Opening Week taking place from Tuesday 18th November to Monday 24th November where visitors will have the opportunity to win prizes and receive storewide discounts at up to 30% off, and of course share ideas and try the latest products before you buy.

Store details:

Location: Chadstone Shopping Centre on Level B1, Site 36. 

Opening hours: Chadstone Opening Hours – see here

ENDS

ASSETS:

X5 Imagery –  HERE

X5 Press Release – HERE

Go Ultra Imagery – HERE

Go Ultra Press Release – HERE

ABOUT INSTA360:
With a “Think bold” mindset, Insta360 empowers people to capture and share their lives in extraordinary ways. Recognized as a market leader and innovator, Insta360’s vast lineup includes the world’s best-selling 360° cameras in the X Series, the thumb-sized GO Series for everyday capture, as well as an extensive range of action cameras, gimbals, webcams, and professional photography solutions. With intuitive, AI-powered software, Insta360 simplifies the creative process, allowing users to focus on storytelling without technical barriers. Insta360 is dedicated to helping a new generation of athletes, creatives, travelers and professionals bring their ideas to life.

Website – https://www.insta360.com/

Instagram – @insta360.anz 

SYDNEY, Nov. 12, 2025 /PRNewswire/ — Suunto announces two new dive computers, Suunto Nautic and Suunto Nautic S. These products mark the beginning of a new dive series designed to meet the evolving needs of recreational and technical divers. Suunto continues its underwater legacy with reliable, durable, and modern tools designed and made in Finland.

Suunto Nautic – a next generation dive computer built for adventure

The Nautic features a 3.26-inch AMOLED display, the largest of its kind on the market. Designed for maximum readability in all diving conditions, it offers sharp 720×382 resolution and an adaptive interface that keeps critical data clearly visible. The Nautic provides up to 120 hours of diving in medium brightness, 90 hours in night conditions, or 80 hours at full brightness.

In addition to core dive features such as single- and multi-gas support, customizable alarms, compass, and wireless tank pressure compatibility, Nautic includes advanced tools for technical diving: customizable views, trimix support, GF99 and SurfGF indicators, decompression planning, and compatibility with closed-circuit rebreathers. It also supports sidemount diving with dual tank pressure display and switch alerts.

The Nautic is equipped with outdoor tools supporting dive planning and preparation, including GPS, maps, tide information, weather forecasts, and sunrise/sunset times, and uses the Bühlmann 16 algorithm with various settings. A built-in LED flashlight adds utility for low-light conditions.

Suunto Nautic S – compact with full dive functionality

The Suunto Nautic S offers similar functionality in a smaller, lightweight format. It features AMOLED display technology and an intuitive interface for divers who prefer compact devices. The Nautic S includes core diving features for both recreational and technical use, including wireless tank pressure support, audio and vibration alarms, dive planning, compass, and sidemount support. It is ideal for freediving, snorkeling, and mermaiding, with features designed for these sports. The Nautic S also features the Bühlmann 16 algorithm, is water-resistant to 100 meters, rated for dives up to 80 meters, and provides up to 60 hours of non-stop diving.

Suunto entered diving in 1965 with the SK-4 compass. In the decades that followed, Suunto introduced pioneering instruments, including the SME dive computer in 1987 and the Suunto Spyder in 1997 – the world’s first watch-sized dive computer. These milestones helped shape modern diving and established Suunto as a trusted companion for divers worldwide.